564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours
| Autor: | Wang, J.S., Barve, M.A., Chiorean, E.G., LoRusso, P., Courtney, K.D., Qi, D., Bullington, J., Sardone, M., Chen, J., Brooks, C., Hoberman, M., Mughal, T.I., Bauer, T.M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S485-S486 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|